Mark Coleman
Director at Axsome Therapeutics, Inc. (AXSM)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $8.2M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jun 10SEC | AXSMAxsome Therapeutics, Inc. | Sell Plan | 64330,389 held (−2%) | $249.00 | $160K | -32.4% |
| Jun 2SEC | AXSMAxsome Therapeutics, Inc. | Sell Plan | 6,00041,140 held (−13%) | $233.46 | $1.4M | -27.9% |
| Jun 2SEC | AXSMAxsome Therapeutics, Inc. | Sell Plan | 6,00035,140 held (−15%) | $230.30 | $1.4M | -26.9% |
| Jun 2SEC | AXSMAxsome Therapeutics, Inc. | Sell Plan | 5,53729,603 held (−16%) | $223.39 | $1.2M | -24.6% |
| Feb 27SEC | AXSMAxsome Therapeutics, Inc. | Sell Plan | 25,00047,140 held (−35%) | $161.11 | $4.0M | +4.5% |
- Sell
Director Mark Coleman sold $160K of AXSM at $249.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Mark Coleman sold $1.4M of AXSM at $233.46 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Mark Coleman sold $1.4M of AXSM at $230.30 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Mark Coleman sold $1.2M of AXSM at $223.39 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Mark Coleman sold $4.0M of AXSM at $161.11 — cuts the stake by 35%; pre-scheduled 10b5-1 plan sale.